<DOC>
	<DOCNO>NCT00389324</DOCNO>
	<brief_summary>This study compare blood level Gamunex patient . Patients take injection skin vein . The study compare safe tolerable two method patient . The patient study defect immune system genetic cause .</brief_summary>
	<brief_title>A Trial Pharmacokinetics , Safety , Tolerability Subcutaneous Gamunex® Primary Immunodeficiency</brief_title>
	<detailed_description>This open-label , single-sequence , multi-center trial subject previously diagnose primary immune deficiency . Subjects IGIV steady state reach time PK profile IV phase occur . Subjects begin SC administration 1 week follow last IV dose follow period six month . PK profile SC phase occur subject reach approximate steady-state SC administration .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<criteria>Adults adolescent ( age 1375 inclusive ) document confirmed preexist diagnosis chronic primary immunodeficiency Previously currently IgG replacement therapy Documented ( within 3 month ) plasma IgG level ≥500 mg/dL current IgG therapy ( IgG level obtain screen visit documentation available ) The medical record subject within previous 2 year available document previous infection treatment Clinical evidence significant acute chronic disease , opinion investigator , may interfere successful completion trial The subject know adverse reaction Gamunex blood product The subject history blistering skin disease , clinically significant thrombocytopenia , bleed disorder , diffuse rash , recurrent skin infection disorder subcutaneous therapy would contraindicate The subject know selective IgA deficiency exception know selective IgA deficient subject previous document eventful reaction product contain IgA The subject pregnant lactate The subject significant proteinuria and/or history acute renal failure and/or severe renal impairment ( BUN creatinine 2.5 time upper limit normal ) and/or dialysis The subject know substance prescription drug abuse past 12 month The subject history current diagnosis deep venous thrombosis The subject acquire medical condition know cause secondary immune deficiency , chronic lymphocytic leukemia , lymphoma , multiple myeloma , chronic recurrent neutropenia ( absolute neutrophil count less 1000 x 10e6/L ) , HIV infection/AIDS The subject receiving follow medication : corticosteroid ( longterm daily , &gt; 1 mg prednisone equivalent/kg/day &gt; 30 day ) ( intermittent course would exclude subject ) ; immunosuppressant ; immunomodulators The subject noncontrolled arterial hypertension ( systolic blood pressure &gt; 160 mmHg and/or diastolic blood pressure &gt; 100 mmHg ) The subject anemia ( hemoglobin &lt; 10 g/dL ) screen The subject participate another clinical trial within 30 day prior screen ( image study without investigative treatment permit ) receive investigational blood product within previous 3 month</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Primary immune deficiency</keyword>
</DOC>